Exenatide is the active ingredient in BYETTA(R) (exenatide) injection, which is currently available in the U.S. and in many countries worldwide for people with type 2 diabetes who are unable to ...

Exenatide is a GLP-1-like (analog) medication primarily prescribed to treat Type 2 diabetes, approved by the U.S. Food and Drug Administration in 2005.

Exenatide, or Byetta, is a synthetic peptide that acts at the receptor for GLP-1 – a hormone that is made in the gastrointestinal track that stimulates insulin secretion and also decreases the ...

Exenatide, an incretin mimetic, was approved by the Food and Drug Administration (FDA) on April 28, 2005, as adjunctive therapy to improve glycemic control in patients with type 2 diabetes mellitus.

Exenatide, the first drug in the new class of incretin mimetics, will be available to pharmacies by June 1 in both a 5- and a 10-μg per dose prefilled pen-injector device.

Since May 2007, a new drug has been available for the treatment of patients with diabetes mellitus type 2 in Germany: exenatide (trade name: Byetta), which is marketed by the manufacturer Eli Lilly.

Exenatide, a glucagon-like peptide-1 agonist (GLP-1 agonist) medication marketed as Byetta® and Bydureon® and used in the treatment of insulin resistance in patients with Type 2 diabetes, ...

To study exenatide's efficacy in reducing hyperglycemia and improving neurologic outcomes, researchers developed the phase 2, international, multicenter, randomized controlled TEXAIS trial.

The Exenatide-PD3 trial randomly assigned 194 Parkinson's patients who were on dopaminergic treatment to either 2 mg of extended-release exenatide by subcutaneous pen injection once weekly (97 ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in ...

The FDA approved exenatide in April 2005 and it was the first incretin mimetic to hit the market. Exenatide (Byetta, Amylin) is synthetic exendin-4, which binds to and activates the pancreatic ...